Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Appointed CFO
Appointed director
RELMADA THERAPEUTICS, INC. (RLMD) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/11/2023 8-K Quarterly results
10/10/2023 8-K Quarterly results
10/04/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "CORPORATE PRESENTATION DATED OCTOBER 4, 2023"
08/10/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "CORPORATE PRESENTATION DATED AUGUST 10, 2023"
08/08/2023 8-K Quarterly results
Docs: "Relmada Therapeutics, Inc. Condensed Consolidated Balance Sheets As of June 30, 2023"
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
07/07/2023 SC 13G/A BlackRock Inc. reports a 2% stake in RELMADA THERAPEUTICS INC
05/30/2023 4 TRAVERSA SERGIO (CEO) has filed a Form 4 on RELMADA THERAPEUTICS, INC.
Txns: Granted 527,211 options to buy @ $3.37, valued at $1.8M
05/30/2023 4 Shenouda Maged (CFO) has filed a Form 4 on RELMADA THERAPEUTICS, INC.
Txns: Granted 317,643 options to buy @ $3.37, valued at $1.1M
05/30/2023 4 SCHMIDT ERIC THOMAS (Director) has filed a Form 4 on RELMADA THERAPEUTICS, INC.
Txns: Granted 92,958 options to buy @ $3.37, valued at $313.3k
05/30/2023 4 Kelly Paul Edward (Director) has filed a Form 4 on RELMADA THERAPEUTICS, INC.
Txns: Granted 92,958 options to buy @ $3.37, valued at $313.3k
05/30/2023 4 GLASSPOOL JOHN (Director) has filed a Form 4 on RELMADA THERAPEUTICS, INC.
Txns: Granted 92,958 options to buy @ $3.37, valued at $313.3k
05/30/2023 4 Fedeli Fabiana (Director) has filed a Form 4 on RELMADA THERAPEUTICS, INC.
Txns: Granted 200,000 options to buy @ $4.22, valued at $844k
05/30/2023 4 Ence Chuck (CA and CO) has filed a Form 4 on RELMADA THERAPEUTICS, INC.
Txns: Granted 321,238 options to buy @ $3.37, valued at $1.1M
05/30/2023 4 CASAMENTO CHARLES J (Director) has filed a Form 4 on RELMADA THERAPEUTICS, INC.
Txns: Granted 92,958 options to buy @ $3.37, valued at $313.3k
05/25/2023 8-K Appointed a new director
Docs: "RELMADA THERAPEUTICS, INC. 2021 EQUITY INCENTIVE PLAN, AS AMENDED"
05/24/2023 4 O'Gorman Cedric (Chief Medical Officer) has filed a Form 4 on RELMADA THERAPEUTICS, INC.
Txns: Bought 10,000 shares @ $3.18, valued at $31.8k
05/15/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "CORPORATE PRESENTATION DATED MAY 15, 2023"
05/11/2023 8-K Quarterly results
Docs: "Relmada Therapeutics, Inc. Condensed Consolidated Balance Sheets As of As of March 31, December 31, 2023 2022 Assets Current assets: Cash and cash equivalents $ 28,894,360 $ 5,395,905 Short-term investments 103,547,634 142,926,781 Other receivables - 512,432 Prepaid expenses 3,089,580 4,035,186 Total current assets 135,531,574 152,870,304 Other assets 34,875 34,875 Total assets $ 135,566,449 $ 152,905,179 Commitments and Contingencies Liabilities and Stockholders’ Equity Current liabilities: Accounts payable $ 4,421,965 $ 5,261,936 Accrued expenses 5,675,292 7,206,941 Total current liabilities 10,097,257 12,468,877 Total liabilities 10,097,257 12,468,877 Stockholders’ Equity: Class A convertible preferred stock, $0.001 par value, 3,500,000 shares authorized, none issued and outstanding - -..."
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/19/2023 8-K Quarterly results
03/31/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
03/31/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/23/2023 10-K Annual Report for the period ended December 31, 2022
03/23/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results CORAL GABLES, Fla., Mar 23, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. , a late-stage biotechnology company addressing diseases of the central nervous system , today provided a corporate update and announced preliminary and unaudited financial results for the fourth quarter and full-year ended December 31, 2022. The Company will host a conference call today, Thursday, March 23, at 4:30 PM Eastern Time/1:30 PM Pacific Time. “Following the availability of top-line results in the Reliance I , one of two Phase 3 sister two-arm, placebo-controlled, pivotal studies evaluating REL-1017 25mg as a potential adjunctive treatment for major depressive disorder , in December 2022, we have..."
03/13/2023 8-K Regulation FD Disclosure  Interactive Data
02/14/2023 SC 13G/A RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in Relmada Therapeutics, Inc.
02/14/2023 SC 13G/A BIOTECHNOLOGY VALUE FUND L P reports a 0% stake in Relmada Therapeutics, Inc.
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023 SC 13G VANGUARD GROUP INC reports a 5% stake in Relmada Therapeutics Inc.
02/06/2023 5/A TRAVERSA SERGIO (CEO) has filed a Form 5/A on RELMADA THERAPEUTICS, INC.
02/02/2023 5 Form 5 - Annual statement of changes in beneficial ownership of securities:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy